Table A.4.

Completion of follow-up status by completion of treatment in the non-North American region (n = 743)^*

	Did not complete treatment (n = 120)		Completed treatment (n = 623)
	Did not complete follow-up (n = 34)	Completed follow-up (n = 86)	Did not complete follow-up (n = 36)	Completed follow-up (n = 587)
Regimen	n (%)	n (%)	n (%)	n (%)
3HP-DOT (n = 389)†	14 (41.2)	35 (40.7)	16 (44.4)	324 (55.2)
9H-SAT (n = 354)†	20 (58.8)	51 (59.3)	20 (55.6)	263 (44.8)
Total (n = 743)	34 (28.3)‡	86 (71.7)‡	36 (5.8)§	587 (94.2)§

^*Participants had the opportunity to continue study follow-up after completion or discontinuation of treatment. Non-completion of follow-up = (34 + 36)/743 = 9.4%. The proportion of non-completion of follow-up between those who did not complete treatment (34/120, 28.3%) vs. those who completed treatment (36/623, 5.8%) was statistically significant (P < 0.001).

^†3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily self-administered INH (maximum dose, 300 mg).

^‡The denominator for the percentage is all participants who did not complete treatment (n = 120).

^§The denominator for the percentage is all participants who completed treatment (n = 623)

H, INH = isoniazid; P, RPT =rifapentine; DOT = directly observed therapy; SAT = self-administered treatment.